Fernández-Teruel, Carlos http://orcid.org/0000-0002-1473-2267
Fudio, Salvador http://orcid.org/0000-0001-7320-6139
Lubomirov, Rubin http://orcid.org/0000-0003-0550-8228
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.
https://doi.org/10.1200/jco.2023.41.16_suppl.8591
Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
https://doi.org/10.1007/s00280-021-04366-3
Safety analysis of lurbinectedin versus topotecan in elderly patients.
https://doi.org/10.1200/jco.2023.41.16_suppl.e20632
Funding for this research was provided by:
PharmaMar
Article History
Received: 6 August 2021
Accepted: 10 October 2021
First Online: 5 November 2021
Declarations
:
: Salvador Fudio and Rubin Lubomirov are employees of Pharma Mar. Carlos Fernández-Teruel is a former employee of Pharma Mar. All authors may hold Pharma Mar stock or stock options.
: All studies were carried out in accordance with principles for human experimentation as defined in the Declaration of Helsinki and were approved by the human investigational review board/ethics committee of each trial center, as required by International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines for Good Clinical Practice.
: Informed consent was obtained from each patient after each was informed of the potential risks and benefits, as well as the investigational nature of each trial.
: The authors affirm that human research participants provided informed consent for publication of the study.